- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
274 |
S.E. Pautler |
|
|
retinal detachment.285,617 Intraoperative risk factors included the use of gas for internal tamponade and creation of iatrogenic retinal break.617 The long-term outcome after vitrectomy is good for up
to 10 years in eyes with good vision and attached retina at the 6-month visit.69,618–620
9.5 Follow-Up Considerations in PDR
Evaluation and management of proliferative diabetic retinopathy over the course of time requires extensive consideration of systemic and ocular factors and the appropriate use of diagnostic testing. Systemic factors include assessment of blood glucose and blood pressure status, extraocular diabetic complications, cardiovascular health, renal function, serum lipid levels, fluid retention, psychological status, pregnancy, medications, and visual needs. Complete routine ocular examination is of paramount importance.
Follow-up interval: The interval between office visits will be determined by the aforementioned factors. Daily to weekly visits are warranted in severe PDR with active neovascularization, e.g., neovascular glaucoma. Monthly to quarterly visits are reasonable as PDR stabilizes. After PRP is complete and NV has regressed, annual visits may be considered for metabolically stable patients.
Pregnancy is associated with progression of PDR. Follow-up examination each trimester or more often is recommended to detect and treat PDR. Diabetic retinopathy tends to stabilize after pregnancy and no long-term severe adverse effects are reported in patients who become pregnant compared to those who do not. Factors for increased risk of progression during pregnancy include duration of diabetes, degree of metabolic control, extraocular complications
of pregnancy, and severity of retinopathy at conception.104,621,622
Ocular factors that may increase the rate of progression and need for close follow-up include intraocular inflammation and cataract surgery.623–627
Refer to the Section 9.6.6 on conditions affecting the presentation of PDR.
Ancillary testing: Complete slitlamp examination with fundoscopy is the primary method of
evaluation; however, ancillary testing may be useful in selected circumstances. Especially in patients who have difficulty in maintaining visual fixation, serial photography helps identify progression of diabetic retinopathy.628 Fluorescein angiography is not required to initiate treatment of PDR, but may be helpful in difficult cases. For example, fluorescein angiography may confirm the presence of suspected new-onset neovascularization presenting with vitreous hemorrhage.629,630 Fluorescein angiography may also help determine the cause of
decreased vision by demonstrating macular capillary dropout.629,631
Optical coherence tomography (OCT) provides useful information in the management of diabetic retinopathy. OCT demonstrates retinal thinning in macular ischemia/atrophy, cystic spaces in macular edema, retinal thickening and surface irregularity
with preretinal membrane, and retinal elevation in cases of vitreoretinal traction.371,390,632–635 Diffi-
culty remains in determining the relative significance of these changes as they relate to visual function, especially in eyes with multiple pathological changes.
Visual field examination by perimetry may be considered in evaluating for driver safety. Although visual acuity may be acceptable, visual field may be compromised to an unsafe degree for driving in patients with advanced PDR.636
9.6Case Management: Decision-Making in Complicated Cases
9.6.1 Cataract and PDR
The coexistence of cataract and PDR is common and requires special consideration.637 Chapter 10 reviews this issue for diabetic retinopathy in general. This section identifies specific issues as they relate to proliferative disease. Although cataract may interfere with visual function and evaluation of the retina, only rarely does cataract interfere with
laser placement, especially with the availability of long wavelength (red) laser.146,147 When cataract
extraction is indicated, the timing of surgery depends on the activity of the PDR.
9 Treatment of Proliferative Diabetic Retinopathy |
275 |
|
|
Optional strategies depend on the relative severity of the cataract and PDR, as well as the presence of
macular edema. The visual prognosis is guarded in this group of eyes.624,638 In general, PDR is treated
with PRP before cataract surgery, but laser may be given by indirect ophthalmoscopic delivery at the time of cataract surgery or at the slitlamp promptly after surgery.639 There is limited information on the optimal sequence of PRP and cataract extraction with regard to the risk of loss of acuity and macular edema.640 Results of cataract surgery with untreated PDR are poor and fraught with progression of PDR and early post-cataract laser may be difficult due to
pain, inflammation, corneal edema, and wound con- cerns.641–643 However, in a small randomized trial,
PRP after cataract extraction was associated with reduced loss of acuity (P ¼ 0.012) and less macular edema (P ¼ 0.033) 12 months after surgery compared with the fellow eye that underwent PRP before cataract extraction.640 If PRP is indicated, but not possible due to poor view through cataract, triamcinolone acetonide or anti-VEGF agents may be injected for short-term stabilization for cataract sur-
gery until laser can be applied postoperatively.218,260,261 These same agents may be helpful in
the short-term management of macular edema exacerbated by cataract surgery.219,644 Intraocular VEGF and other cytokine levels are elevated following diabetic cataract surgery.645 Poor metabolic control is associated with an increased risk of progression of diabetic retinopathy after cataract surgery.646 However, efforts to improve short-term worsening of diabetic retinopathy and maculopathy by rapid improvement in glycolic control prior to cataract extraction appear to be ineffective, if not harmful.647
If vitrectomy surgery is indicated, cataract surgery before or during vitrectomy lowers the rate of repeat vitrectomy compared to phakic vitrectomy,
possibly due to improved access to the peripheral retina in the non-phakic eye.314,330,648,649 Sequential
cataract surgery followed by vitrectomy has the disadvantage of two separate visits to the operating suite, but may diminish the inflammation and complications seen with combined surgery.650 Sequential surgeries may be facilitated by the use of triamcinolone acetonide and anti-VEGF injection as noted above.
Cataract extraction at the time of vitrectomy may speed the recovery of vision in selected
cases.314,651 Extracapsular cataract extraction or phacoemulsification with posterior chamber lens implantation may be combined with vitrectomy surgery.652 However, there appears to be an increased rate of intraoperative lens capsular tears and zonulysis as well as postoperative inflammation, poster-
ior synechiae formation, and posterior capsular fibrosis.314,548,650,653 A poor red reflex in eyes with
vitreous hemorrhage makes cataract surgery more challenging.314 Combined procedures with extracapsular cataract extraction appear to create more inflammation than with phacoemulsification.551 Aggressive management of inflammation is needed with consideration for the use of triamcinolone
injection, which may also help control the increased incidence of macular edema.654–656 Combined pha-
coemulsification/vitrectomy may be especially suitable in a patient presenting with cataract and indications for diabetic vitrectomy in the presence of poor vision in the fellow eye.314
Combined vitrectomy with pars plana lensectomy is another alternative. This approach involves less anterior segment manipulation and, therefore, may cause less anterior chamber inflammation. The anterior capsule may be retained for the placement
of a ciliary sulcus lens implant at the time of vitrectomy or subsequently.657–660 This approach has been
reported to be successful in highly complicated cases with combined traction–rhegmatogenous retinal detachment requiring silicone oil injection.330 Limited data show no definitive advantage of pars plana lensectomy compared with trans-corneal phacoemulsification.661,662 However, there may be less anterior chamber inflammation and fibrin deposition associated with pars plana lensectomy.552
Cataract surgery performed on an elective basis after vitrectomy generally produces improved vision. However, capsular tears and zonulysis complicate surgery in approximately 10% of cases,
increasing the risk of posterior dislocation of lens fragments or lens implant.650,663
Regardless of the relative timing of cataract and vitrectomy surgery, complications may occur. Postoperative anterior capsular contraction occurs more often in eyes with diabetic retinopathy and may
result in traction on the ciliary body with hypotony and ciliary effusion.664,665 With appropriate use of
PRP, the risk of rubeosis and neovascular glaucoma is minimized. The ETDRS reported NVI/NVG in
276 |
S.E. Pautler |
|
|
6% of eyes after cataract extraction.69,666 Small retrospective studies report similar low incidence of NVI/NVG, the risk of which correlates directly
with the severity of PDR and indirectly with the amount of PRP.69,667,668 With meticulous attention
to completing PRP including the anterior periphery, the incidence of NVI/NVG may be decreased to less than 1%.314 Finally, the risk of retinal detachment of approximately 5% following diabetic vitrectomy
appears to be unaffected by the addition of cataract extraction.314,585
In the ETDRS, the visual outcome is related directly to the severity of diabetic retinopathy. Two hundred and seventy eyes were studied prospectively. One-year after cataract surgery, 55% of eyes with advanced diabetic retinopathy (severe NPDR or worse) experienced improved vision. The distribution of visual acuities in this group was as follows: 25% >20/40, 42% >20/100, and 22% 5/200 or worse.666 Others estimate that patients with PDR are 30 times less likely to achieve 20/40 or better vision compared with diabetic patients without retinopathy. Compounding the problem is evidence that some patients with advanced PDR who undergo phacoemulsification may not experience improved visual function despite improvement in measured visual acuity.669
The effect of cataract surgery on progression of diabetic retinopathy is uncertain. The ETDRS showed a trend of borderline significance toward short-term worsening of diabetic retinopathy. The study showed no long-term increased prevalence of diabetic macular edema, but the study was not designed to detect an early increase in macular edema or an increase in severity of edema in the long term.666 Others have provided conflicting evidence of progression of diabetic retinopathy after cataract surgery (for further discussion the reader is referred to Chapter 10).
9.6.2Dense Vitreous Hemorrhage and Untreated PDR
The presence of dense vitreous hemorrhage in an eye with untreated PDR not only causes acute severe loss of vision but also places the eye in a
category at high risk for potential persistent visual loss.65,66,102 There are several options to reach the
goal of clearing the vitreous hemorrhage and applying PRP. Elevation of the head at night or patching with strict bed rest may help clear the hemorrhage for office-based PRP.287 Anti-VEGF agents may be injected to cause short-term involution of neovas-
cularization while waiting for hemorrhage to clear.210,263 Purified ovine hyaluronidase has been
shown to speed the resolution of vitreous hemor- rhage.277–279 The status of the vitreous may play a
role in the decision to intervene with vitrectomy. If a complete PVD is present, observation may be pre-
ferable to vitrectomy, especially if the fellow eye has good vision.38,74 If severe PDR is suspected based on
the history of type 1 diabetes, iris neovascularization, or extensive vitreoretinal traction seen on B-scan, early vitrectomy is indicated.69,74 Previtrectomy intravitreal injection of bevacizumab may be considered prior to surgery in these high-risk cases.248 On the other hand, the echographic finding of tractional retinal detachment may argue against anti-VEGF therapy.273 If vitrectomy is necessary, even partial preoperative PRP may improve outcome.184
9.6.3Untreated PDR with Diabetic Macular Edema
The presence of diabetic macular edema in eyes with PDR is indicative of increased severity of retinopathy with increased risk of retinopathy progression and severe visual loss compared to eyes with the same stage of retinopathy without edema. Panretinal photocoagulation (PRP) is useful to prevent profound loss of vision in PDR, but may increase macular edema and decrease visual acuity in a doserelated fashion.67 For eyes with high-risk PDR, the ETDRS recommended macular focal/grid laser for clinically significant macular edema (CSME) at the initial session with the option of starting PRP for PDR in the nasal quadrants during the same session. PRP in the temporal quadrants was deferred for at least 2 weeks.68 The ETDRS cautioned against delaying PRP for high-risk PDR with CSME. For eyes approaching, but not reaching high-risk PDR, the peripheral scatter treatment was not started until the edema had resolved after
9 Treatment of Proliferative Diabetic Retinopathy |
277 |
|
|
which ‘‘mild scatter’’ (lower density, fewer burns) treatment was applied. Retreatment in these eyes was only given if progression in retinopathy was documented. This treatment plan was shown to reduce the rate of severe visual loss compared to deferral of treatment.67
Small studies show that intravitreal triamcino-
lone decreases macular thickening and prevents worsening of vision after PRP.221,670–674 A small,
randomized, controlled, clinical trial demonstrated a significant benefit of triamcinolone acetonide in preventing decreased vision and increased macular edema following PRP and focal laser for eyes with PDR and CSME.221 The benefits of this treatment must be balanced by the risks including cataract, glaucoma, and endophthalmitis.211 An alternative to prophylactic treatment is rescue treatment with triamcinolone acetonide after PRP treatment if macular edema worsens with decreased vision. However, triamcinolone acetonide may be considered primarily as an adjunct to macular focal laser in the treatment of diabetic macular edema.233 AntiVEGF agents may be considered for a similar adjunctive role in the management of these difficult cases.241 This topic is also discussed in Chapter 7.
9.6.4PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
There is an established role for early vitrectomy in the management of severe fibrovascular proliferation (FVP) and traction retinal detachment (TRD).72 Pan-
retinal photocoagulation improves outcome despite
potential short-term risks. 17,49,69,176,183,184,406,407
Open to question is the role of anti-VEGF therapy. Although some have reported beneficial results with bevacizumab in these cases, there is anecdotal evi-
dence of progression of TRD with anti-VEGF injection.243,272,273 Until further research allows for risk
stratification, bevacizumab should be used with caution. In cases of severe traction detachment with or without rubeosis, silicone oil tamponade may be useful for prolonged tamponade and for sequestration of fibrovascular growth factors until laser treatment has taken effect.442
9.6.5 PDR with Neovascular Glaucoma
Panretinal photocoagulation and peripheral retinal cryopexy play a key role in the management of active
new vessel growth in neovascular glaucoma (NVG).285,675 Extensive PRP is needed to treat the
widespread areas of capillary dropout in these cases.17 Indeed, prevention of NVG with appropriate timing and extent of PRP is preferable to treating established NVG.69 New to the armamentarium are the anti-
VEGF agents, which cause dramatic short-term resolution of neovascularization.248–250,267,269,270 Their
role may be best suited to minimize progression of angle neovascularization and secondary synechiae formation while peripheral laser/cryopexy takes effect.210 Retinal detachment is associated with rubeosis and repair of the detachment may induce regression of the rubeosis.676 Retinal tamponade with silicone oil is useful in these cases.442
When significant anterior synechiae block the trabecular meshwork, intervention is directed at destruction of the ciliary body to decrease aqueous production or at providing alternative routes for aqueous drainage. Surgery may lower IOP, but visual prognosis is grim.69 Many surgical procedures are available to lower IOP, some of which are employed by the vitreoretinal surgeon. The reader is referred to Chapter 11 for further discussion.
9.6.6Conditions Altering the Clinical Course of PDR
‘‘Early worsening’’ with improved metabolic control: The primary issue in managing rapid worsening of diabetic retinopathy is identifying conditions in which rapid worsening might occur and initiating prompt treatment with PRP. Although improved metabolic control is associated with improved long-term outcome, ‘‘early worsening’’ was described in patients assigned to tight control in the Diabetes Control and Complications Trial.8 The effect of early worsening of diabetic retinopathy was reversed by 18 months and did not result in serious visual loss.6 Successful pancreas transplant
surgery leads to improved control with the potential for short-term worsening of retinopathy.677–681
278 |
S.E. Pautler |
|
|
Pregnancy: There is an increased short-term risk of progression of diabetic retinopathy with pregnancy. The increased risk may continue for up to 1 year, but no long-term adverse effects of pregnancy were reported by the Diabetes Control and Complications Trial.106 Additional factors that may increase the risk of progression in pregnancy include duration of diabetes (>10–15 years), poor glycemic control, hypertension, and
the presence of moderate–to-severe NPDR at baseline.105,682 Therefore, prompt PRP is indi-
cated in pregnant patients with severe NPDR or early PDR.69
Carotid atherosclerosis: Atherosclerosis of the carotid artery may affect retinal vascular perfusion by embolization or stenosis.683 Emboli may be liberated from an atherosclerotic plaque and occlude the central retinal artery or a branch retinal arteriole. In the presence of diabetic retinopathy, this added ischemic insult may
precipitate neovascularization (Fig. 9.32).50,684–687 Alternatively, if profound neurosensory apoptosis results from central retinal artery occlusion prior to the onset of diabetic retinopathy, there may be a protective effect against progression of diabetic retinopathy (Fig. 9.33).
There are conflicting reports regarding the effect of carotid stenosis on diabetic retinopathy. Most recent reports indicate carotid stenosis is associated
with ipsilateral worsening of diabetic retinopa- thy.173,688–691 However, relative ipsilateral sparing
from diabetic retinopathy has also been described.692–696 A possible explanation for these conflicting reports is presented in the Box. Systemic evaluation of patients presenting with asymmetric diabetic retinopathy may include non-invasive carotid Doppler ultrasonography. However, only a minority of patients with asymmetric diabetic retinopathy test positive for significant carotid occlusive disease.690
a |
b |
c |
d |
Fig. 9.32 Apparent asymmetric diabetic retinopathy. Ischemic retinal whitening superior to left disk (a) due to branch retinal artery occlusion with symptomatic inferior visual field loss. Mild NPDR is seen on fluorescein angiogram (b) along with delayed circulation time in superior
hemispheric retinal vasculature. Several months later, the patient returned with further loss of vision OS due to vitreous hemorrhage from disk neovascularization (d). The right eye had mild NPDR (c). Note: photographic artifacts are seen centrally in macula OS and near disk OD
9 Treatment of Proliferative Diabetic Retinopathy |
279 |
|
|
a |
b |
Fig. 9.33 Asymmetric diabetic retinopathy. Right eye (a) suffered from profound loss of vision many years ago due to central retinal artery occlusion with resultant pale disk and attenuated arterioles. Subsequently, less severe retinopathy
developed in the right eye compared with the left eye (b), which had progressed to high-risk PDR requiring panretinal photocoagulation
Why are there conflicting reports regarding the effect of carotid stenosis on the severity of diabetic retinopathy? One explanation for this discrepancy may involve differences in time of onset and relative severity of the two pathologies. For example, if moderate carotid stenosis occurs before the onset of diabetic retinopathy, an ipsilateral decrease in the severity of diabetic retinopathy may be
expected on the basis of protection against the known adverse effects of hypertension on diabetic retinopathy.56,697,698 Conceivably, the degree of carotid stenosis may not be severe enough to cause
venous stasis retinopathy. Conversely, if significant diabetic retinopathy is present prior to severe carotid occlusion, the added ischemic insult might precipitate a progression of the retinopathy ipsilateral to the carotid stenosis. Additional confusion may result from the similarity of venous stasis retinopathy to diabetic retinopathy. Venous stasis retinopathy, an uncommon manifestation of severe carotid stenosis, may cause blot hemorrhages and microaneurysms, but the findings tend to be ipsilateral to the stenotic artery and show midperipheral predominance.699
Neovascular glaucoma in diabetes may be caused by PDR or ocular ischemic syndrome (OIS). Findings suggestive of OIS as the primary cause include an unexpected low intraocular pressure and ipsilateral bright-light amaurosis, both likely due to poor ocular perfusion.700–703 Revascularization of the occluded carotid artery may result in improved vision. However, complications may be encountered with improvement in perfusion. For example, an abrupt increase in intraocular pressure may occur
following carotid surgery if extensive posterior synechiae are present.691,701,704 Rarely, diabetic macular
edema becomes manifest after endarterectomy.705
Miscellaneous ocular and systemic conditions: A variety of ocular conditions may affect PDR.
Conditions associated with extensive destruction or thinning of the retina provide protection against the development of PDR. They include high myopia, previous central retinal artery occlusion (Fig. 9.33), advanced glaucoma (Fig. 9.34), optic atrophy, rod–
cone degeneration, and extensive chorioretinal scarring from trauma or past inflammation.13,172,173,706
Asteroid hyalosis may increase the risk of developing PDR, probably due to the associated lower prevalence of posterior vitreous detachment.38,173
Ocular inflammation generally appears to accelerate diabetic retinopathy in conditions such as anterior
uveitis, posterior uveitis, surgery, and endophthalmi- tis.623,625–627,643,707 A possible link is the common
elevation of cellular fibronectin and adrenomedullin
